CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis
Canadian Journal of Cardiology2020Vol. 36(2), pp. 159–169
Citations Over TimeTop 10% of 2020 papers
Eileen O’Meara, Michael McDonald, Michael Chan, Anique Ducharme, Justin A. Ezekowitz, Nadia Giannetti, Adam Grzeslo, George Heckman, Jonathan G. Howlett, Sheri L. Koshman, Serge Lepage, Lisa Mielniczuk, Gordon W. Moe, Elizabeth Swiggum, Mustafa Toma, Sean Virani, Shelley Zieroth, Sabe De, Sylvain Matteau, Marie‐Claude Parent, Anita Asgar, Gideon Cohen, Nowell M. Fine, Margot K. Davis, Subodh Verma, David Z.I. Cherney, Howard Abrams, Abdul Al‐Hesayen, Alain Cohen‐Solal, Michel D’Astous, Diego Delgado, Olivier Desplantie, E. Estrella-Holder, Lee A. Green, Haissam Haddad, Karen Harkness, Adrian F. Hernandez, Simon Kouz, Marie-Hélène Leblanc, Douglas S. Lee, Frederick A. Masoudi, Robert S. McKelvie, Miroslaw Rajda, Heather J. Ross, Bruce Sussex
Related Papers
- → The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials(2021)88 cited
- → Sympathoinhibitory effect of sacubitril-valsartan in heart failure with reduced ejection fraction: A pilot study(2021)15 cited
- → Heart failure with preserved ejection fraction after the PARAGON-HF trial results: current knowledge and future directions(2020)3 cited
- → Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?(2020)